179 related articles for article (PubMed ID: 36926262)
21. The determinants of very severe immune-related adverse events associated with immune checkpoint inhibitors: A prospective study of the French REISAMIC registry.
Ruste V; Goldschmidt V; Laparra A; Messayke S; Danlos FX; Romano-Martin P; Champiat S; Voisin AL; Baldini C; Massard C; Laghouati S; Marabelle A; Lambotte O; Michot JM
Eur J Cancer; 2021 Nov; 158():217-224. PubMed ID: 34627664
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of Readministration of Immune Checkpoint Inhibitors After Immune-Related Adverse Events in Patients With Cancer.
Simonaggio A; Michot JM; Voisin AL; Le Pavec J; Collins M; Lallart A; Cengizalp G; Vozy A; Laparra A; Varga A; Hollebecque A; Champiat S; Marabelle A; Massard C; Lambotte O
JAMA Oncol; 2019 Sep; 5(9):1310-1317. PubMed ID: 31169866
[TBL] [Abstract][Full Text] [Related]
23. Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: Case series and literature review.
Kitagawa S; Hakozaki T; Kitadai R; Hosomi Y
Thorac Cancer; 2020 Jul; 11(7):1927-1933. PubMed ID: 32421224
[TBL] [Abstract][Full Text] [Related]
24. Immune-related adverse events associated with immune checkpoint inhibitors: An updated comprehensive disproportionality analysis of the FDA adverse event reporting system.
Chen C; Wu B; Zhang C; Xu T
Int Immunopharmacol; 2021 Jun; 95():107498. PubMed ID: 33725634
[TBL] [Abstract][Full Text] [Related]
25. Treatment- and immune-related adverse events of immune checkpoint inhibitors in advanced lung cancer.
Shao J; Wang C; Ren P; Jiang Y; Tian P; Li W
Biosci Rep; 2020 May; 40(5):. PubMed ID: 32315071
[TBL] [Abstract][Full Text] [Related]
26. Immune-Related Adverse Events in PD-1 Treated Melanoma and Impact Upon Anti-Tumor Efficacy: A Real World Analysis.
Bastacky ML; Wang H; Fortman D; Rahman Z; Mascara GP; Brenner T; Najjar YG; Luke JJ; Kirkwood JM; Zarour HM; Davar D
Front Oncol; 2021; 11():749064. PubMed ID: 34900695
[TBL] [Abstract][Full Text] [Related]
27. Side effect management during immune checkpoint blockade using CTLA-4 and PD-1 antibodies for metastatic melanoma - an update.
Kähler KC; Hassel JC; Heinzerling L; Loquai C; Thoms KM; Ugurel S; Zimmer L; Gutzmer R;
J Dtsch Dermatol Ges; 2020 Jun; 18(6):582-609. PubMed ID: 32489011
[TBL] [Abstract][Full Text] [Related]
28. Safety and Efficacy of Checkpoint Inhibition in Patients With Melanoma and Preexisting Autoimmune Disease : A Cohort Study.
van der Kooij MK; Suijkerbuijk KPM; Aarts MJB; van den Berkmortel FWPJ; Blank CU; Boers-Sonderen MJ; van Breeschoten J; van den Eertwegh AJM; de Groot JWB; Haanen JBAG; Hospers GAP; Piersma D; van Rijn RS; Ten Tije AJ; van der Veldt AAM; Vreugdenhil G; van Zeijl MCT; Wouters MWJM; Dekkers OM; Kapiteijn E
Ann Intern Med; 2021 May; 174(5):641-648. PubMed ID: 33587686
[TBL] [Abstract][Full Text] [Related]
29. Safety of immune checkpoint inhibitor rechallenge after discontinuation for grade ≥2 immune-related adverse events in patients with cancer.
Allouchery M; Lombard T; Martin M; Rouby F; Sassier M; Bertin C; Atzenhoffer M; Miremont-Salame G; Perault-Pochat MC; Puyade M;
J Immunother Cancer; 2020 Dec; 8(2):. PubMed ID: 33428586
[TBL] [Abstract][Full Text] [Related]
30. Immune Checkpoint Inhibitors and Immune-Related Adverse Events in Patients With Advanced Melanoma: A Systematic Review and Network Meta-analysis.
Chang CY; Park H; Malone DC; Wang CY; Wilson DL; Yeh YM; Van Boemmel-Wegmann S; Lo-Ciganic WH
JAMA Netw Open; 2020 Mar; 3(3):e201611. PubMed ID: 32211869
[TBL] [Abstract][Full Text] [Related]
31. Prevalence, therapy and tumour response in patients with rheumatic immune-related adverse events following immune checkpoint inhibitor therapy: a single-centre analysis.
Verspohl SH; Holderried T; Behning C; Brossart P; Schäfer VS
Ther Adv Musculoskelet Dis; 2021; 13():1759720X211006963. PubMed ID: 33912248
[TBL] [Abstract][Full Text] [Related]
32. Extended Follow-Up of Chronic Immune-Related Adverse Events Following Adjuvant Anti-PD-1 Therapy for High-Risk Resected Melanoma.
Goodman RS; Lawless A; Woodford R; Fa'ak F; Tipirneni A; Patrinely JR; Yeoh HL; Rapisuwon S; Haydon A; Osman I; Mehnert JM; Long GV; Sullivan RJ; Carlino MS; Menzies AM; Johnson DB
JAMA Netw Open; 2023 Aug; 6(8):e2327145. PubMed ID: 37535354
[TBL] [Abstract][Full Text] [Related]
33. Risk of Immune-related Adverse Events in Melanoma Patients With Preexisting Autoimmune Disease Treated With Immune Checkpoint Inhibitors: A Population-based Study Using SEER-Medicare Data.
Tully KH; Cone EB; Cole AP; Sun M; Chen X; Marchese M; Roghmann F; Kilbridge KL; Trinh QD
Am J Clin Oncol; 2021 Aug; 44(8):413-418. PubMed ID: 34081033
[TBL] [Abstract][Full Text] [Related]
34. Interleukin-6 blockade for prophylaxis and management of immune-related adverse events in cancer immunotherapy.
Dimitriou F; Hogan S; Menzies AM; Dummer R; Long GV
Eur J Cancer; 2021 Nov; 157():214-224. PubMed ID: 34536945
[TBL] [Abstract][Full Text] [Related]
35. Neurologic Serious Adverse Events Associated with Nivolumab Plus Ipilimumab or Nivolumab Alone in Advanced Melanoma, Including a Case Series of Encephalitis.
Larkin J; Chmielowski B; Lao CD; Hodi FS; Sharfman W; Weber J; Suijkerbuijk KPM; Azevedo S; Li H; Reshef D; Avila A; Reardon DA
Oncologist; 2017 Jun; 22(6):709-718. PubMed ID: 28495807
[TBL] [Abstract][Full Text] [Related]
36. Prospective evaluation of the prognostic value of immune-related adverse events in patients with non-melanoma solid tumour treated with PD-1/PD-L1 inhibitors alone and in combination with radiotherapy.
Schweizer C; Schubert P; Rutzner S; Eckstein M; Haderlein M; Lettmaier S; Semrau S; Gostian AO; Frey B; Gaipl US; Zhou JG; Fietkau R; Hecht M
Eur J Cancer; 2020 Nov; 140():55-62. PubMed ID: 33045663
[TBL] [Abstract][Full Text] [Related]
37. Meta-analysis of immune-related adverse events of immune checkpoint inhibitor therapy in cancer patients.
Song P; Zhang D; Cui X; Zhang L
Thorac Cancer; 2020 Sep; 11(9):2406-2430. PubMed ID: 32643323
[TBL] [Abstract][Full Text] [Related]
38. A multicenter characterization of hepatitis associated with immune checkpoint inhibitors.
Patrinely JR; McGuigan B; Chandra S; Fenton SE; Chowdhary A; Kennedy LB; Mooradian MJ; Palmeri M; Portal D; Horst SN; Scoville EA; Long GV; Shi C; Mehnert JM; Sullivan RJ; Salama AK; Sosman JA; Menzies AM; Johnson DB
Oncoimmunology; 2021 Feb; 10(1):1875639. PubMed ID: 33628621
[TBL] [Abstract][Full Text] [Related]
39. Atypical Presentations and Management of Endocrine and Hepatic Immune-Related Adverse Events From Adjuvant Immune Checkpoint Inhibitor Therapy in Stage III Resected Melanoma.
Kottschade LA; Yan Y
JCO Oncol Pract; 2020 Feb; 16(2_suppl):10s-14s. PubMed ID: 32045536
[TBL] [Abstract][Full Text] [Related]
40. Chronic Immune-Related Adverse Events Following Adjuvant Anti-PD-1 Therapy for High-risk Resected Melanoma.
Patrinely JR; Johnson R; Lawless AR; Bhave P; Sawyers A; Dimitrova M; Yeoh HL; Palmeri M; Ye F; Fan R; Davis EJ; Rapisuwon S; Long GV; Haydon A; Osman I; Mehnert JM; Carlino MS; Sullivan RJ; Menzies AM; Johnson DB
JAMA Oncol; 2021 May; 7(5):744-748. PubMed ID: 33764387
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]